Bexion Pharmaceuticals, Inc. to Participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum
COVINGTON, Ky., Oct. 12, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum. The conference will be held virtually, from October 17-18, 2023.
Scott Shively, CEO and President of Bexion Pharmaceuticals, and Joyce LaViscount, Chief Financial Officer of Bexion Pharmaceuticals, will attend the conference.
About Bexion Pharmaceuticals
Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion currently has three clinical trials open for enrollment.
Investor Contact:
William Windham
Solebury Strategic Communications
646-378-2946
[email protected]
Media Contact:
Joyce LaViscount
Bexion Pharmaceuticals
859-446-7386
[email protected]
SOURCE Bexion Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article